PTP-Pez: A novel regulator of TGFβ signaling

Cell Cycle

Volumn 7, Issue 15, 2008, Pages 2290-2295

  Wyatt, Leila ^a   Khew Goodall, Yeesim ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Cancer; Development; EMT; Fibrosis; TGF ; Tyrosine phosphatase

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE PEZ; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CELL CYCLE PROGRESSION; COLORECTAL CANCER; CYTOKINE PRODUCTION; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; GENE MUTATION; HOMEOSTASIS; HUMAN; NONHUMAN; ORGANOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TRANSCRIPTION REGULATION;

DANIO RERIO;

EID: 48849087797     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6443     Document Type: Review

References (61)

1. Smith AL, Mitchell PJ, Shipley J, Gusterson BA, Rogers MV, Crompton MR. Pez: a novel human cDNA encoding protein tyrosine phosphatase- and ezrin-like domains. Biochem Biophys Res Commun 1995; 209:959-65.
2. Moller NP, Moller KB, Lammers R, Kharitonenkov A, Sures I, Ullrich A. Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain. Proc Natl Acad Sci USA 1994; 91:7477-81.
3. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 2004; 117:699-711.
4. Ogata M, Takada T, Mori Y, Oh-hora M, Uchida Y, Kosugi A, Miyake K, Hamaoka T. Effects of overexpression of PTP36, a putative protein tyrosine phosphatase, on cell adhesion, cell growth, and cytoskeletons in HeLa cells. J Biol Chem 1999; 274:12905-9.
5. Ogata M, Takada T, Mori Y, Uchida Y, Miki T, Okuyama A, Kosugi A, Sawada M, Oh-hora M, Hamaoka T. Regulation of phosphorylation level and distribution of PTP36, a putative protein tyrosine phosphatase, by cell-substrate adhesion. J Biol Chem 1999; 274:20717-24.
6. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. Translocation of protein tyrosine phosphatase Pez/PTPD2/PTP36 to the nucleus is associated with induction of cell proliferation. J Cell Sci 2000; 113:3117-23.
7. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. The protein tyrosine phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates beta-catenin. Mol Biol Cell 2003; 14:2520-9.
8. Sjoblom T, Jones S, Wood L, Williams Parsons D, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willison JKV, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW and Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.
9. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B. and Velculescu VE. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304:1164-6.
10. Wyatt L, Wadham C, Crocker LA, Lardelli M and Khew-Goodall Y. The protein tyrosine phosphatase Pez regulates TGFbeta, epithelial-mesenchymal transition, and organ development. J Cell Biol 2007; 178:1223-35.
11. Bierie B and Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6:506-20.
12. Rahimi RA and Leof EB. TGFbeta signaling: a tale of two responses. J Cell Biochem 2007; 102:593-608.
13. Moustakas A and Heldin CH. Non-Smad TGFbeta signals. J Cell Sci 2005; 118:3573-84.
14. Massagué J. TGFbeta signal transduction. Annu Rev Biochem 1998; 67:753-91.
15. Yang Y, Pan X, Lei W, Wang J and Song J. Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 2006; 25:7235-44.
16. Zavadil J and Bottinger EP. TGFbeta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24:5764-74.
17. Siegel PM and Massague J. Cytostatic and apoptotic actions of TGFbeta in homeostasis and cancer. Nat Rev Cancer 2003; 3:807-21.
18. Siegenthaler JA and Miller MW. Transforming growth factor beta1 promotes cell cycle exit through the cyclin-dependent kinase inhibitor p21 in the developing cerebral cortex. J Neurosci 2005; 25:8627-36.
19. Siegenthaler JA and Miller MW. Transforming growth factor beta1 modulates cell migration in rat cortex: effects of ethanol. Cereb Cortex 2004; 14:791-802.
20. Daniel CW, Robinson S and Silberstein GB. The role of TGFbeta in patterning and growth of the mammary ductal tree. J Mammary Gland Biol Neoplasia 1996; 1:331-41.
21. Mishra L, Shetty K, Tang Y, Stuart A and Byers SW. The role of TGFbeta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005; 24:5775-89.
22. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005; 233:706-20.
23. Kaartinen V, Cui XM, Heisterkamp N, Groffen J and Shuler CF. Transforming growth factor-beta3 regulates transdifferentiation of medial edge epithelium during palatal fusion and associated degradation of the basement membrane. Dev Dyn 1997; 209:255-60.
24. Boyer AS, Ayerinskas II, Vincent EB, McKinney LA, Weeks DL and Runyan RB. TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol 1999; 208:530-45.
25. Camenisch TD, Molin DG, Person A, Runyan RB, Gittenberger-de Groot AC, McDonald JA and Klewer SE. Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 2002; 248:170-81.
26. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Müller GA, Strutz F and Kalluri R. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001; 159:1313-21.
27. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H and Kalluri R. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282:23337-47.
28. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S and Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13:952-61.
29. Biswas SCTL, Wang SE and Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 2006; 12:4142-6.
30. Fleisch MC, Maxwell CA and Barcellos-Hoff MH. The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer 2006; 13:379-400.
31. Aigner L and Bogdahn U. TGFbeta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res 2008; 331:225-41.
32. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M and Kaibara N. An elevated serum level of transforming growth factor-beta1 (TGFbeta1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000; 20:4489-93.
33. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM and Slawin KM. Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGFbeta1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy. Journal of Clinical Oncology 2001; 19:2856-64.
34. Shariat SF, Kim J, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP and Slawin KM. Preoperative Plasma Levels of Transforming Growth Factor beta1 Strongly Predict Clinical Outcome in Patients with Bladder Carcinoma. Cancer 2001; 92:2985-92.
35. Ivanovic V, Demajo M, Krtolica K, Krajnovic M, Konstantinovic M, Baltic V, Prtenjak G, Stojiljkovic B, Breberina M, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D and Dimitrijevic B. Elevated plasma TGFbeta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006; 371:191-3.
36. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL. Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor beta1. Mol Cell Biol 2003; 23:8691-703.
37. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA and Arteaga CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004; 64:9002-11.
38. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-54.
39. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB and Roberts AB. Transforming growth factor beta1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988; 263:7741-6.
40. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M and Roberts AB. Autoinduction of transforming growth factor beta1 is mediated by the AP-1 complex. Mol Biol Cell 1990; 10:1492-7.
41. Flanders KC, Holder MG and Winokur TS. Autoinduction of mRNA and protein expression for transforming growth factor-beta S in cultured cardiac cells. J Mol Cell Cardiol 1995; 27:805-12.
42. Liu G, Ding W, Neiman J and Mulder KM. Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGFbeta) induction of TGFbeta3 secretion. J Biol Chem 2006; 281:29479-90.
43. Fraser D, Wakefield L and Phillips A. Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and platelet-derived growth factor. Am J Pathol 2002; 161:1039-49.
44. Dubois CM, Laprise MH, Blanchette F, Gentry LE and Leduc R. Processing of transforming growth factor beta1 precursor by human furin convertase. J Biol Chem 1995; 270:10618-24.
45. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F and Seidah NG. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 2001; 158:305-16.
46. Lyons RM, Gentry LE, Purchio AF and Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta1 by plasmin. J Cell Biol 1990; 110:1361-7.
47. Miyazono K, Olofssen A, Colosetti P and Heldin CH. A role of the latent TGFbeta1-binding protein in the assembly and secretion of TGFbeta1. EMBO J 1991; 10:1091-101.
48. Yin W, Smiley E, Germiller J, Mecham RP, Florer JB, Wenstrup RJ and Bonadio J. Isolation of a novel latent transforming growth factor-beta binding protein gene (LTBP-3). J Biol Chem 1995; 270:10147-60.
49. Giltay R, Kostka G and Timpl R. Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins. FEBS Lett 1997; 411:164-8.
50. Taipale J, Miyazono K, Heldin CH and Keski-Oja J. Latent transforming growth factor-beta1 associates to fibroblast extracellular matrix via latent TGFbeta binding protein. J cell Biol 1994; 124:171-81.
51. Annes JP, Munger JS and Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116:217-24.
52. Yu Q and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGFbeta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14:163-76.
53. Souchelnitskiy S, Chambaz EM and Feige JJ. Thrombospondins selectively activate one of the two latent forms of transforming growth factor-beta present in adrenocortical cellconditioned medium. Endocrinology 1995; 136:5118-26.
54. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB and Sheppard D. The integrin alphavbeta6 binds and activates latent TGFbeta1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96:319-28.
55. Annes JP, Chen Y, Munger JS and Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGFbeta requires the latent TGFbeta binding protein-1. J Cell Biol 2004; 165:723-34.
56. Fontana L, Chen Y, Prijatelj P, Sakai T, Fässler R, Sakai LY and Rifkin DB. Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGFbeta complexes containing LTBP-1. FASEB J 2005; 19:1798-808.
57. Barcellos-Hoff MH and Dix TA. Redox-mediated activation of latent transforming growth factor-beta1. Mol Endocrinol 1996; 10:1077-83.
58. Lawrence DA, Pircher R and Jullien P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun 1985; 133:1026-34.
59. Teuchert M, Schafer W, Berghöfer S, Hoflack B, Klenk HD and Garten W. Sorting of furin at the trans-Golgi network. Interaction of the cytoplasmic tail sorting signals with AP-1 Golgi-specific assembly proteins. J Biol Chem 1999; 274:8199-207.
60. Kruljac-Letunic A, Moelleken J, Kallin A, Wieland F and Blaukat A. The tyrosine kinase Pyk2 regulates Arf1 activity by phosphorylation and inhibition of the Arf-GTPase-activating protein ASAP1. J Biol Chem 2003; 278:29560-70.
61. Dorner C, Ciossek T, Müller S, Møller PH, Ullrich A and Lammers R. Characterization of KIF1C, a new kinesin-like protein involved in vesicle transport from the Golgi apparatus to the endoplasmic reticulum. J Biol Chem 1998; 273:20267-75.